New concept for ALK negative anaplastic large cell lymphoma.
- Author:
Xiao-Wen TANG
1
;
Xiao-Lan SHI
;
De-Pei WU
Author Information
1. Department of Hematology, Jiangsu Institute of Hematology, Suzhou 215006, Jiangsu Province, China.
- Publication Type:Journal Article
- MeSH:
Biomarkers, Tumor;
Humans;
Lymphoma, Large B-Cell, Diffuse;
classification;
pathology;
Lymphoma, Large-Cell, Anaplastic;
classification;
pathology
- From:
Journal of Experimental Hematology
2011;19(2):511-516
- CountryChina
- Language:Chinese
-
Abstract:
ALK negative anaplastic large cell lymphoma (ALK(-) ALCL) lacks the specific expression of ALK protein, although it also strongly expresses CD30 and resembles the morphologic characteristics of ALK positive anaplastic large cell lymphoma (ALK(+) ALCL). Recently, some new researches indicate that there exist molecular and genetic differences between these two types of ALCL. Moreover, the treatment response, prognosis, and long-term survival of ALK(-) ALCL are far worse than that of ALK(+) ALCL, such as ALK(-) ALCL is associated with older age persons, B group syndrome, disease advanced stage, high International Prognostic Index (IPI) and poor prognosis (< 49% 5-year survival). As a consequence, some new advances on basis (cell morphology and tissue pathology, immunophenotypes, cell genetics and molecular marker), diagnosis and treatment of ALK(-) ALCL are summarized in this review.
